Workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis

  • Email
  • Help

Details

TitleWorkshop on the clinical investigation of new medicines for the treatment of multiple sclerosis
Date17/10/2013 - 17/10/2013
LocationEuropean Medicines Agency, London, UK
SummaryThe main goal of the workshop is to make sure that in the revision of the multiple-sclerosis guideline, the European Medicines Agency can take the most up-to-date, state-of-the-art scientific developments in multiple sclerosis into consideration, as well as the positions of experts in the field on the main topics in the guideline.

All documents

Name Language First published Last updated
Agenda - Programme - European Medicines Agency workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis (English only) 07/10/2013  
Summaries of the presentations - European Medicines Agency workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis (English only) 07/10/2013  
Invitation for expressions of interest - European Medicines Agency workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis (English only) 20/06/2013  
Presentation - Disability assessment: can we combine responsiveness and clinical relevance? (Bernard Uitdehaag) (English only) 12/11/2013  
Presentation - Cognition and fatigue as major determinants of disability (Bernd C. Kieseier) (English only) 12/11/2013  
Presentation - Optical coherence tomography: A role in monitoring multiple sclerosis (Celia Oreja-Guevara) (English only) 12/11/2013  
Presentation - New perception of disability – including cognition, fatigue, pain and other impairments related to multiple sclerosis (Diego Cadavid) (English only) 12/11/2013  
Presentation - Patient-reported outcomes, biomarkers and novel methodologies, and their role in the development of new multiple sclerosis medicines (Frank Dahlke) (English only) 12/11/2013  
Presentation - The staggered two-step approach for treatments with profound effect on immunity (Gavin Giovannoni) (English only) 12/11/2013  
Presentation - Critical review of outcomes used in MS clinical trials (George Ebers) (English only) 12/11/2013  
Presentation - The new outcome measures in MS: possible better ways to assess disability that overcome the limitations of the EDSS (Gilmore O'Neill) (English only) 12/11/2013  
Presentation - Changes in Patient Population - Insufficient Treatment Response (Gordon Francis) (English only) 12/11/2013  
Presentation - The proposed ‘two-step approach’ for MS treatments with a significant effect on immunity (Hideki Garren) (English only) 12/11/2013  
Presentation - Multi-arm trials with repurposed drugs in progressive MS (Jeremy Chataway) (English only) 12/11/2013  
Presentation - Approaches to advancing patient focussed outcomes assessment in clinical trials (Jeremy Hobart) (English only) 12/11/2013  
Presentation - Treatment guidelines for relapsing MS and the ‘two step approach’ for disease modifying therapy (Klaus Schmierer) (English only) 12/11/2013  
Presentation - How to evaluate medications in Multiple Sclerosis when placebo controlled RCTs are not feasible (Luca Massacesi) (English only) 12/11/2013  
Presentation - Design strategies to minimise the use of placebo in MS clinical trials (Maria Pia Sormani) (English only) 12/11/2013  
Presentation - Assessing benefit/risk profile of novel immunomodulatory drugs with significant efficacy but potential risks. What data should be presented at MAA? (Michael Panzara) (English only) 12/11/2013  
Presentation - Issues regarding use of placebo in multiple sclerosis drug trials (Peter Scott Chin) (English only) 12/11/2013  
Presentation - Clinical development issues in progressive multiple sclerosis(Volker Knappertz) (English only) 12/11/2013  

Media Videos


Related information